Following activation, a subset of B cells undergoes differentiation to become plasma cells. This transformation is driven by cytokines and co-stimulatory signals, such as those received from T helper cells. These signals activate specific transcription factors, like Blimp-1 and XBP-1, which orchestrate the transition into antibody-producing factories.
Morphological and Functional Changes:
The activated B cell to plasma cell transition involves dramatic changes, both in structure and function:
Increased Endoplasmic Reticulum (ER): The ER is the site of antibody assembly. Plasma cells significantly expand their ER network to accommodate the high rate of antibody production.
Increased Golgi Apparatus: The Golgi apparatus modifies and packages proteins for secretion. Plasma cells also enlarge their Golgi apparatus to efficiently package and export the large number of antibodies they produce.
Reduced Ribosomes: Activated B cells possess numerous ribosomes for protein synthesis, but plasma cells drastically reduce the number of ribosomes as they shift their focus solely to antibody production.
Abundant Rough Endoplasmic Reticulum (RER): The RER is the part of the ER involved in protein synthesis and is studded with ribosomes. While the overall number of ribosomes decreases, the proportion of RER within the ER increases in plasma cells due to its critical role in antibody production.
Loss of Antigen Presentation Machinery: Activated B cells can present antigen fragments to T cells. However, plasma cells lose this capability as they focus solely on antibody production.
Functional Specialization:
Antibody Production: Plasma cells become highly specialized factories dedicated to the production and secretion of large quantities of antibodies specifically targeted against the encountered antigen. This massive antibody production requires increased metabolic activity to fuel the cellular processes involved.
Short Lifespan: Unlike memory B cells which can persist for years, plasma cells have a relatively short lifespan, typically lasting several days to weeks. This ensures a controlled immune response and prevents excessive antibody production.1
Following their rapid production within plasma cells, antibodies embark on a crucial journey. Inside these specialized cells, newly synthesized antibody chains undergo complex folding and assembly, aided by chaperone proteins. Additionally, sugar molecules are attached to the antibodies in the Golgi apparatus, enhancing their stability and functionality. These assembled and modified antibodies are then meticulously packaged into vesicles within the Golgi, ready for transport. Upon receiving specific signals, these vesicles fuse with the plasma cell membrane, releasing the antibodies through a process called exocytosis. The released antibodies can travel to various locations in the body depending on their type. Some circulate freely in the bloodstream, patrolling for invaders, while others accumulate in specific tissues like mucous membranes, providing localized defenses.2
Once released, antibodies play a vital role in combating pathogens. They can directly bind to and neutralize specific antigens on pathogens, rendering them inactive. Additionally, they can act as opsonins, marking pathogens for destruction by immune cells like macrophages, or even trigger the complement system, a cascade of proteins that further aids in pathogen elimination. The intricate mechanisms of antibody secretion and release thus ensure their efficient delivery and deployment, empowering them to effectively neutralize pathogens and protect the body from infections.
References:
Cavacini, L. (2010). Structure and Function of Immunoglobulins. The Journal of Allergy and Clinical Immunology, 125(2 0 2), S41. https://doi.org/10.1016/j.jaci.2009.09.046
Nutt, S. L., Hodgkin, P. D., Tarlinton, D. M., & Corcoran, L. M. (2015). The generation of antibody-secreting plasma cells. Nature Reviews Immunology, 15(3), 160-171. https://doi.org/10.1038/nri3795
The therapeutic efficacy of antibodies is closely related to their ability to recognize and bind specific epitopes on target antigens. Epitopes, or antigenic determinants, are a group of amino acids or other chemical groups that are part of a molecule to which an antibody attaches itself. Epitope characterization can help reveal the mechanism of antibody binding and apply intellectual property (patent) protection for novel antibodies, in addition to designing antibodies with high specificity and minimal cross-reactivity.
Understanding the differences between antibody specificity and selectivity is essential for designing and interpreting antibody-based assays in research for experimental accuracy and data interpretation. Antibody specificity refers to an antibody's ability to recognize and bind to a particular epitope—a unique part of an antigen that elicits an immune response.
Antibody-based assays are essential tools in biomedical research, providing the means to detect, quantify, and visualize specific proteins or antigens within complex biological samples. These assays' efficacy hinges on the antibodies' precise properties. While affinity, avidity, specificity, and selectivity are fundamental to antibody performance, the ultimate impact of these properties is heavily influenced by the experimental context in which the antibody is employed.
Biologics, particularly antibodies, have become indispensable in biomedical research and therapeutic development. Research-use-only (RUO) biologics play a pivotal role in preclinical studies, providing researchers with the necessary tools to explore antibody functions and therapeutic potential in vivo.
ScientistとScience Exchangeとのご利用可能です。
